Despite waning public concern six years after the onset of the COVID-19 pandemic and three years into the endemic phase, the World Health Organization (WHO) continues to emphasize the virus’s ongoing risk, particularly for vulnerable populations, and recommends sustained preventative vaccination efforts.
The continued caution stems from the virus’s evolution into an endemic respiratory illness, similar to influenza, characterized by recurring variants and sustained transmission. According to data from the Korea Disease Control and Prevention Agency’s hospital-level surveillance, COVID-19 accounted for 8,632 hospitalizations in 2023, ranking as the third most prevalent acute respiratory infection after rhinovirus (13,535) and influenza virus (11,773).
The risk of severe illness, including hospitalization and death, remains significantly elevated for older adults and individuals with underlying health conditions. Age-related immune decline and chronic inflammation contribute to reduced immune function and impaired viral clearance in the elderly. Individuals with pre-existing conditions such as hypertension and diabetes also face a substantially increased risk of mortality upon COVID-19 infection.
The ongoing emergence of viral variants and the waning of vaccine-induced immunity underscore the need for continued vaccination. The South Korean government has responded by incorporating COVID-19 vaccination into the National Immunization Program (NIP), effective this season. This provides free access to vaccination for individuals aged 65 and over, those with immunocompromising conditions, and residents of long-term care facilities.
While many assume COVID-19 vaccination is limited to the autumn and winter months, free vaccinations remain available through April 2024 for eligible individuals who missed the initial campaign. This is due to the virus’s demonstrated ability to circulate during the summer months, unlike influenza, necessitating year-round preparedness.
One of the vaccines available through the NIP is Pfizer’s Comirnaty, which has been administered in over 5 billion doses globally over the past five years, with a well-established safety profile and consistent efficacy demonstrated through clinical trials and real-world data. The current seasonal vaccine, Comirnaty LP.8.1, is specifically designed to target the LP.8.1 variant, as recommended by the WHO and the Korean Society of Infectious Diseases.
A phase 3 clinical trial demonstrated that Comirnaty elicited a more than fourfold increase in neutralizing antibodies against LP.8.1 fourteen days post-vaccination in 100 participants aged 65 and older, or with at least one underlying condition that increased their risk of severe COVID-19.
The vaccine is now available in a pre-filled syringe formulation, streamlining the administration process. Unlike previous vial-based formulations requiring manual syringe filling, the pre-filled syringes reduce the potential for medication errors and expedite vaccine delivery, enhancing convenience for both healthcare providers and patients.
“The risk of severe COVID-19 remains substantial for high-risk groups, such as the elderly and immunocompromised, making vaccination a critical preventative measure,” stated Dr. Kim Tae-hyung, an infectious disease specialist at Soonchunhyang University Seoul Hospital. “I strongly recommend that individuals in these groups complete their vaccination as soon as possible.”
Dr. Kim further emphasized that, “While many perceive COVID-19 as a receding threat, respiratory viruses are inherently unpredictable. Continued vigilance and preparedness are essential, even with relatively low current transmission rates. A shift in public perception and increased vaccination rates are crucial.”
